The Federal Circuit upheld the PTAB's ruling on Novartis's U.S. Patent No. 9,220,631, affirming that the claims were unpatentably obvious, despite arguments against prior art.
Rejecting Novartis's teaching-away argument, the court underscored that negative descriptions in prior art do not preclude a finding of obviousness in patent claims.
[
Collection
]
[
|
...
]